Covenant Asset Management’s VanEck Biotech ETF BBH Stock Holding History

Covenant Asset Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,892	Closed	-$236K	–	150
2017 Q4	$236K	Buy	+1,892	New	+$242K	0.14%	133

Other funds holding BBH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

BRM

Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return

Covenant Asset Management's BBH Position: Q1 2018 in Review

Covenant Asset Management sold out of VanEck Biotech ETF (BBH) in Q1 2018, closing a stake of 1,892 shares — an estimated $236K sold.

Covenant Asset Management first reported a position in BBH in Q4 2017 and held it in 1 quarter. The position peaked at $236K in Q4 2017. 82 funds tracked by Wall St. Rank hold BBH as of Q1 2018.

Covenant Asset Management reported no remaining VanEck Biotech ETF position as of Q1 2018 after selling out during the quarter.
Covenant Asset Management sold 1,892 VanEck Biotech ETF shares in Q1 2018, an estimated $236K.
Covenant Asset Management first reported a position in VanEck Biotech ETF in Q4 2017 and held it in 1 quarter.
Covenant Asset Management's VanEck Biotech ETF position peaked at $236K in Q4 2017.
82 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2018.

Based on Covenant Asset Management's 13F filing for Q1 2018, filed 4 May 2018.